BS_J8G4SH4Z
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 38.633377135348226
- age_years
- 12.605
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.505
- G2M_CHECKPOINT+0.443
- MYC_TARGETS_V1+0.386
- DNA_REPAIR+0.372
- SPERMATOGENESIS+0.227
- MITOTIC_SPINDLE+0.190
- PROTEIN_SECRETION+0.140
- OXIDATIVE_PHOSPHORYLATION+0.076
- PANCREAS_BETA_CELLS+0.060
- UNFOLDED_PROTEIN_RESPONSE+0.038
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.741
- INTERFERON_GAMMA_RESPONSE-0.678
- INFLAMMATORY_RESPONSE-0.617
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.608
- TNFA_SIGNALING_VIA_NFKB-0.593
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.567
- ANGIOGENESIS-0.538
- IL2_STAT5_SIGNALING-0.503
- COAGULATION-0.490
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GNV89A5P | medulloblastoma | — | 0.994 |
| 2 | BS_HD4EJYE3 | medulloblastoma | — | 0.990 |
| 3 | BS_4CP4T22V | medulloblastoma | — | 0.990 |
| 4 | BS_HF3RNN2T | medulloblastoma | — | 0.990 |
| 5 | BS_HTEPAKCM | medulloblastoma | — | 0.989 |
| 6 | BS_DFWFBYSN | medulloblastoma | — | 0.988 |
| 7 | BS_KYF0Q0E7 | medulloblastoma | — | 0.984 |
| 8 | BS_5PJCHF6V | medulloblastoma | — | 0.979 |
| 9 | BS_Y8D1F5WW | medulloblastoma | — | 0.977 |
| 10 | BS_G00FHF3Q | medulloblastoma | — | 0.976 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.505 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.443 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.386 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.372 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.227 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.076 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.038 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.017 | Inavolisib | — uncovered |